Novartis Fabhalta® (iptacopan) Meets Phase III Primary Endpoint
Novartis Fabhalta® (iptacopan) has achieved its primary endpoint in a Phase III trial, demonstrating its ability to slow kidney function decline in patients with IgA nephropathy (IgAN).
As a leading innovative medicines company, Novartis strives to reimagine medicine, improving and extending people's lives, and empowering patients, healthcare professionals, and societies in the face of serious diseases.
With its medicines reaching 296 million people worldwide, Novartis provides various resources, including:
- Clinical trial recruiting and managed access programs for patients and their caregivers
- Funding opportunities for patient organizations and side effects reporting
- Clinical trial recruiting, grant funding, congresses, and country-level information for physicians and healthcare professionals
Discover how Novartis turns breakthrough science into transformative, high-value treatments.
Novartis is committed to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards, as outlined in the Novartis in Society Integrated Report.
Author's summary: Novartis Fabhalta® shows promise in slowing kidney function decline.
More News
- DOJ to officially ask grand jury to indict former Trump advisor John Bolton
- CBS Staffers 'Won't Be Punished' for Not Responding to Bari Weiss
- “Brewers Karen” Loses Her Job After She Was Caught On Video Saying “Let’s Call ICE” On An American War Veteran At NLCS Game
- HILL, THOMPSON: Taxpayers should know how much their municipal governments spend
- Bucks' formidable draft curse just claimed its next victim
- Fall into art at the 45th Annual Setauket Artists exhibit | TBR News Media
- Huntsman Mental Health Institute at the University of Utah Welcomes Steve Eliason as Inaugural Senior Director of Behavioral Health Policy
- Claim misleads about ‘mortgage fraud’ on Trump’s Cabinet
- What's your big election question for Connolly and Humphreys? Let us know
- Former Auburn coach Bruce Pearl to become national TV analyst